Nautilus Biotechnology (NAUT) Cash from Financing Activities (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Cash from Financing Activities of $244000.0 for Q2 2026, down 77.92% sequentially from $1.1 million in Q1 2026, and up 156.84% YoY from $95000.0 in Q2 2025.
Nautilus Biotechnology (NAUT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Cash from Financing Activities for 7 years, with the latest figure at $244000.0 in Q2 2026.
- Quarterly Cash from Financing Activities rose 156.84% year-over-year to $244000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 million (up 109.24% YoY) and the FY2025 annual result came in at $214000.0, down 81.29% from the prior year.
- Cash from Financing Activities fell to $244000.0 in Q2 2026 per NAUT's latest filing, from $1.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $1.1 million in Q1 2026 and troughed at $1000.0 in Q1 2023.
- A 5-year average of $213941.2 and a median of $140000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities tumbled 99.94% in 2022, then surged 24400.0% in 2024.
- Over 5 years, Cash from Financing Activities stood at $135000.0 in 2022, then soared by 87.41% to $253000.0 in 2023, then jumped by 73.91% to $440000.0 in 2024, then sank by 77.05% to $101000.0 in 2025, then jumped by 141.58% to $244000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $244000.0, $1.1 million, and $101000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | 244,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 244,000.00 |
| Jun 30, 2026 | 244,000.00 |
| Mar 31, 2026 | 1.11 Mn |
| Mar 31, 2026 | 1.11 Mn |
| Dec 31, 2025 | 101,000.00 |
| Dec 31, 2025 | 101,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | 440,000.00 |
| Dec 31, 2024 | 440,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 253,000.00 |
| Dec 31, 2023 | 253,000.00 |